Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 625 participants.
Also called NCT02486445
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 625 participants
- Sponsor
- Ostfold Hospital Trust
- Registry
-
NCT02486445
-
- Other papers using this trial's data
- Clinical use and safety of empiric anticoagulation during diagnostic work-up for deep vein thrombosis
- Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Norway
- Registry status
- Completed
Technical summary
Registry record NCT02486445. Allocation not applicable; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2018-11-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study
- Acronym
- Ri-Schedule
- Condition
- Deep Venous Thrombosis
- Intervention (Drug)
- Rivaroxaban
- Lead sponsor
- Ostfold Hospital Trust
Record details
- Record id
cardio:ct-nct02486445- Content hash
ae5f64dee18d86a33d9c852b3d0bcdf05c04bf54c3b5ee9b693b85bf7a57a90f